The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 811-816

  Sjöström, Johanna ^a   Von Boguslawski, Kristina ^a   Saksela, Eero ^a   Blomqvist, Carl ^b   Bengtsson, Nils Olof ^c   Malmström, Per ^d   Mjaaland, Ingvil ^e   Ostenstadt, Björn ^f   Wist, Erik ^g   Valvere, Vahur ^h   Takayama, Shinichi ⁱ   Reed, John C ⁱ  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^h Estonian Cancer Center   (Estonia)

ⁱ BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BAG 1 PROTEIN; CELL PROTEIN; DOCETAXEL; ESTROGEN RECEPTOR; FAS ANTIBODY; FAS LIGAND; FLUOROURACIL; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; CARRIER PROTEINS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE GLYCOPROTEINS; METHOTREXATE; MIDDLE AGED; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 0036300989     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
2. p53 status and the efficacy of cancer therapy in vivo
3. Mechanisms of apoptosis
4. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity
5. Fas expression and function in normal and malignant breast cell lines
6. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors
7. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer
8. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis
9. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
10. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised Phase III study with crossover on progression by the Scandinavian Breast Group
11. Reporting results of cancer treatment
12. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines
13. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells
14. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide
15. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
16. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
17. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
18. Prediction of response to primary chemotherapy for operable breast cancer
19. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy
20. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer
21. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
22. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer
23. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
24. BAG-1: A novel biomarker predicting long-term survival in early-stage breast cancer
25. Expression of BAG-1 in invasive breast carcinomas
26. FasL:Fas ratio: A prognostic factor in breast carcinomas
27. Apoptosis by death factor